- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: KB-003 | KB003
Compound class: Antibody
Comment: Lenzilumab is a fully human IgG1κ moncolonal antibody targeting granulocyte-macrophage colony-stimulating factor (GM-CSF), being investigated for its immunomodulatory potential.
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide searches using the variable regions of the heavy and light chains of the antibody reveal exact matches with sequences submitted with patent US8075885 B2 .
|No information available.|
|Summary of Clinical Use|
|Lenzilumab has completed Phase II clinical trial for uncontrolled asthma, whereas a Phase II study in patients with inadequately controlled rheumatoid arthritis has been terminated. A Phase I trial in patients with previously treated chronic myelomonocytic leukemia (CMML) is ongoing .|
|Mechanism Of Action and Pharmacodynamic Effects|
|The antibody functionally neutralizes soluble GM-CSF. The potential clinical utility of anti-GM-CSF therapy is discussed in .
In CMML, cancer cells are hypersensitive to GM-CSF, with their cell growth and survival stimulated in the presence of very low levels of this cytokine. Using lenzilumab to neutralise GM-CSF in in vitro experiments kills CMML cells.